Clinical Trial Update: A Study for Patients Who Completed VITALITY-ALS (CY 4031) [Phase 3]

View source ↗

Summary

Phase 3 trial update for patients who completed VITALITY-ALS (CY 4031); study completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• CY 4031 (VITALITY-ALS program)

Snippet

Sponsor: Cytokinetics | Conditions: Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Status: COMPLETED | Results posted: 2021-05-12